M. Talbott

发表

Tumor suppressor immune gene therapy to reverse immunotherapy resistance

J. Nemunaitis, S. Chada, C. Yun, 2021, medRxiv.

Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy

D. Morgan, J. Greer, S. Huntington, 2012, Leukemia & lymphoma.

Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies

J. Warner, B. Tillman, M. Talbott, 2018, European journal of haematology.

Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations

M. Talbott, N. Reddy, Andrew B Bodiford, 2015 .

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

M. Talbott, N. Reddy, Andrew B Bodiford, 2014, OncoTargets and therapy.

Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia

M. Chernick, C. Presant, A. Raptis, 2013, Leukemia & lymphoma.

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

J. Armitage, H. Rugo, G. Lyman, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma

J. Nemunaitis, S. Chada, D. Wiederhold, 2021, medRxiv.

Myeloid growth factors.

J. Armitage, M. Dwyer, H. Rugo, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Thyroid Dysfunction in Patients with Diffuse Large B-Cell Lymphoma Receiving Lenalidomide May be Mediated By TNF-α

K. Richards, Megan L. Hames, K. Dahlman, 2014 .

Durable responses in refractory autoimmune hemolytic anemia with alemtuzumab

M. Talbott, N. Reddy, Renee McAlister, 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.

K. Richards, Megan L. Hames, K. Dahlman, 2015, Experimental hematology.

Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations

M. Talbott, N. Reddy, Andrew B Bodiford, 2015 .

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

M. Talbott, N. Reddy, Andrew B Bodiford, 2014, OncoTargets and therapy.

Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations

M. Talbott, Andrew B Bodiford, Nishitha M Reddy, 2015 .